NCT04779242

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 670 (actual)
• Sponsor: Paratek Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Conditions

• Community-acquired Pneumonia
• Bacterial Pneumonia

Interventions

Type	Name	Description
DRUG	Omadacycline	IV for injection, oral tablets
DRUG	Moxifloxacin	IV solution, oral tablets

Timeline

• Start date: 2021-02-25
• Primary completion: 2024-03-27
• Completion: 2024-03-27
• First posted: 2021-03-03
• Last updated: 2025-04-09
• Results posted: 2025-04-09

Locations

55 sites across 8 countries: Bulgaria, Croatia, Georgia, Hungary, Poland, Russia, Serbia, Ukraine

Regulatory

• FDA-regulated drug study